CA2926199C - Therapy with cells from human placenta and hematopoietic cells - Google Patents

Therapy with cells from human placenta and hematopoietic cells Download PDF

Info

Publication number
CA2926199C
CA2926199C CA2926199A CA2926199A CA2926199C CA 2926199 C CA2926199 C CA 2926199C CA 2926199 A CA2926199 A CA 2926199A CA 2926199 A CA2926199 A CA 2926199A CA 2926199 C CA2926199 C CA 2926199C
Authority
CA
Canada
Prior art keywords
cells
subject
ucb
placental perfusate
cord blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2926199A
Other languages
English (en)
French (fr)
Other versions
CA2926199A1 (en
Inventor
Jodi P. Gurney
Xiaokui Zhang
Stacy HERB
Robert J. Hariri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celularity Inc
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity Inc filed Critical Celularity Inc
Publication of CA2926199A1 publication Critical patent/CA2926199A1/en
Application granted granted Critical
Publication of CA2926199C publication Critical patent/CA2926199C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2926199A 2013-10-03 2014-10-02 Therapy with cells from human placenta and hematopoietic cells Active CA2926199C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361886648P 2013-10-03 2013-10-03
US61/886,648 2013-10-03
US201361890057P 2013-10-11 2013-10-11
US61/890,057 2013-10-11
PCT/US2014/058774 WO2015051088A1 (en) 2013-10-03 2014-10-02 Therapy with cells from human placenta and hematopoietic cells

Publications (2)

Publication Number Publication Date
CA2926199A1 CA2926199A1 (en) 2015-04-09
CA2926199C true CA2926199C (en) 2022-05-17

Family

ID=52779130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2926199A Active CA2926199C (en) 2013-10-03 2014-10-02 Therapy with cells from human placenta and hematopoietic cells

Country Status (12)

Country Link
US (1) US10179152B2 (https=)
EP (1) EP3052109B8 (https=)
JP (4) JP2016531889A (https=)
KR (3) KR20220044384A (https=)
CN (1) CN105792834A (https=)
AU (3) AU2014329513A1 (https=)
CA (1) CA2926199C (https=)
DK (1) DK3052109T3 (https=)
MX (2) MX2016004209A (https=)
RU (2) RU2019131152A (https=)
WO (1) WO2015051088A1 (https=)
ZA (1) ZA201602151B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10426796B2 (en) 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US11285177B2 (en) 2018-01-03 2022-03-29 Globus Medical, Inc. Allografts containing viable cells and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
IL107483A0 (en) * 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2004071283A2 (en) * 2003-02-13 2004-08-26 Anthrogenesis Corporation Use of umbilical cord blood to treat individuals having a disease, disorder or condition
CN101389754A (zh) * 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
WO2007089627A2 (en) * 2006-01-27 2007-08-09 Auxocell Laboratories, Inc. Methods and compositions relating to stem cell transplantation
EP2023717B1 (en) * 2006-05-11 2016-04-13 Anthrogenesis Corporation Methods for collecting placenta cord blood stem cells
NZ599825A (en) * 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

Also Published As

Publication number Publication date
RU2016116816A3 (https=) 2018-08-02
CA2926199A1 (en) 2015-04-09
ZA201602151B (en) 2022-12-21
KR20220044384A (ko) 2022-04-07
MX2021003798A (es) 2021-05-27
US10179152B2 (en) 2019-01-15
EP3052109A1 (en) 2016-08-10
AU2020202076A1 (en) 2020-04-09
JP2016531889A (ja) 2016-10-13
NZ718571A (en) 2023-12-22
JP2021107407A (ja) 2021-07-29
AU2014329513A1 (en) 2016-04-28
EP3052109A4 (en) 2017-05-03
WO2015051088A1 (en) 2015-04-09
EP3052109B1 (en) 2021-05-12
KR20160102965A (ko) 2016-08-31
JP2023078156A (ja) 2023-06-06
EP3052109B8 (en) 2021-06-23
US20160235790A1 (en) 2016-08-18
MX2016004209A (es) 2016-07-11
RU2019131152A3 (https=) 2022-02-24
JP2019194211A (ja) 2019-11-07
DK3052109T3 (da) 2021-08-16
KR20210054046A (ko) 2021-05-12
RU2016116816A (ru) 2017-11-13
RU2019131152A (ru) 2019-11-11
CN105792834A (zh) 2016-07-20
AU2022215207A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
AU2022215207A1 (en) Therapy with cells from human placenta and hematopoietic cells
Barker et al. A “no-wash” albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions
Elchalal et al. Postpartum umbilical cord blood collection for transplantation: a comparison of three methods
Storb et al. Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells
Lew et al. Implementation of an obstetric cell salvage service in a tertiary women’s hospital
Sreelakshmi et al. Acute hypotension associated with leucocyte depletion filters during cell salvaged blood transfusion
Dhot et al. Cord blood stem cell banking and transplantation
HK1227309B (en) Therapy with cells from human placenta and hematopoietic cells
HK1227309A1 (en) Therapy with cells from human placenta and hematopoietic cells
Sivakumaran et al. Umbilical cord blood banking and its therapeutic uses
EP3068432A2 (en) Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
Winkler Red Blood Cell Transfusion
Cogliano-Shutta et al. Bone Marrow Transplantation An Overview and Comparison of Autologous, Syngeneic, and Allogeneic Treatment Modalities
Katzenstein et al. Haploidentical related umbilical cord blood stem cell transplant in a child with acute non-lymphocytic leukemia
CN104721232A (zh) 脐带血免疫细胞在制备治疗银屑病药物中的应用
TW202120108A (zh) 心血管疾病之治療
Eze et al. Umbilical Cord Blood Collection Protocol and the Impact on the Nucleated and Progenitor Cell Quantity and Quality
Dasari et al. Prevention of transfusion reactions and in post transfusion reactions, promoting patient safety [3P’s]
Wacharaprechanont et al. Cord blood collection for the national cord blood bank in Thailand
Norville et al. Hematopoietic stem cell transplantation
Makmom et al. Assembling the granulocyte avengers: a case series of apheresis granulocyte collection (AGC) preparation for granulocyte transfusion (GTX) in severe neutropenic paediatric patients at University Malaya Medical Centre (UMMC).
Ferguson et al. and Manipulation
Andritsos et al. Collection, processing, and infusion of adult hematopoietic stem cells (bone marrow and peripheral blood stem cells)
RU2590688C2 (ru) Способ получения суспензии ядросодержащих клеток из пуповинной крови со стандартизированной концентрацией
Shivaram OF TRANSFUSION (SHOT)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190923

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250403

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: T-6-6-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20251107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251107

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: T-6-6-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260421

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260421